Mosayebnia, M., Rezaeianpour, S., Rikhtechi, P., Hajimahdi, Z., Beiki, D., Kobarfard, F., Sabzevari, O., Amini, M., Abdi, K., Shahhosseini, S. (2018). Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods. Iranian Journal of Pharmaceutical Research, 17(3), 917-926. doi: 10.22037/ijpr.2018.2276
Mona Mosayebnia; Sedigheh Rezaeianpour; Pedram Rikhtechi; Zahra Hajimahdi; Davood Beiki; Farzad Kobarfard; Omid Sabzevari; Mohsen Amini; Khosrou Abdi; Soraya Shahhosseini. "Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods". Iranian Journal of Pharmaceutical Research, 17, 3, 2018, 917-926. doi: 10.22037/ijpr.2018.2276
Mosayebnia, M., Rezaeianpour, S., Rikhtechi, P., Hajimahdi, Z., Beiki, D., Kobarfard, F., Sabzevari, O., Amini, M., Abdi, K., Shahhosseini, S. (2018). 'Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods', Iranian Journal of Pharmaceutical Research, 17(3), pp. 917-926. doi: 10.22037/ijpr.2018.2276
Mosayebnia, M., Rezaeianpour, S., Rikhtechi, P., Hajimahdi, Z., Beiki, D., Kobarfard, F., Sabzevari, O., Amini, M., Abdi, K., Shahhosseini, S. Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods. Iranian Journal of Pharmaceutical Research, 2018; 17(3): 917-926. doi: 10.22037/ijpr.2018.2276
Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods
1Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences,Tehran.Iran.
2Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Behesti University of Medical Sciences,Tehran,Iran.
3Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Behesti University of Medical Sciences,tehran,Iran.
4Research Institute for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences
6Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
7Associate professor of Medicinal Chemistry Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
8Department of Radiopharmacy and Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
9Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Behesti University of Medical Sciences, Tehran, Iran.
10Protein Technology Research Center, Shahid Behesti University of Medical Sciences, Tehran, Iran.
Abstract
The basic chemical structure of most prostate specific membrane antigen (PSMA) inhibitors which are now in pre-clinical and clinical studies is Glu-Ureido-based peptides. Synthesis of urea-based PSMA inhibitors includes two steps: 1- isocyanate intermediate formation and 2- urea bond formation. In current methods, isocyanate is formed in liquid phase and then reacts with amine existing in liquid phase or bound to solid phase for urea bond formation. In this study, we developed a new facile method for formation of both isocyanate and urea on solid phase under standard peptide coupling conditions. The solid phase-bound isocyanate served as intermediate to form urea bond. To monitor reaction progress qualitative test (Kaiser Test) and On-Bead FT-IR spectroscopy were used. The structure of Glutamate-Urea-Lysine (EUK) was confirmed using LC-Mass and 1H-NMR. This novel method successfully applied to synthesize of another urea-based peptide containing a sequence of Glu-Urea-Lys(OMe)-GABA-Tyr-Tyr-GABA and the bifunctional linker hydrazinonicotinamide (HYNIC) as well.